Liraglutide Safety in Adolescents (12 to 17): What Parents and Clinicians Need to Know

Why Adolescent Safety Data Matters for Liraglutide

Prescribing any GLP-1 receptor agonist to a patient whose body is still growing demands a different evidence standard than adult use. Adolescents between 12 and 17 are navigating puberty, linear growth, bone mineral accrual, and neurodevelopmental change. A drug that is well-tolerated in a 45-year-old may behave differently in a 14-year-old.

The American Academy of Pediatrics (AAP) 2023 Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents with Obesity recommended pharmacotherapy for adolescents aged 12 and older with obesity when lifestyle interventions alone have not achieved adequate weight reduction 1. Liraglutide 3.0 mg became the first GLP-1 receptor agonist approved for this population when the FDA extended the Saxenda label in December 2020, based on the SCALE Teens trial 2. Before that approval, no GLP-1 agonist had undergone a dedicated Phase 3 pediatric obesity trial with a full 56-week safety follow-up.

The distinction between adult and adolescent data is not academic. Growth plate closure, pubertal hormone surges, and the higher prevalence of mood disorders in teenagers create safety questions that adult trials cannot answer. Every section below draws primarily from adolescent-specific evidence.

The SCALE Teens Trial: Design and Safety Outcomes

The SCALE Teens trial (NCT02918279) enrolled 251 adolescents aged 12 to 17 with a BMI corresponding to 30 kg/m² or greater by adult equivalent and at least one weight-related comorbidity, or a BMI corresponding to 35 kg/m² or greater regardless of comorbidities 2. Participants were randomized 1:1 to liraglutide 3.0 mg or placebo, both combined with lifestyle therapy, for 56 weeks of treatment followed by 26 weeks of off-drug follow-up.

The primary efficacy endpoint was change in BMI standard deviation score (BMI-SDS). The liraglutide group achieved a reduction of −0.22 in BMI-SDS compared with +0.14 in the placebo group (estimated treatment difference: −0.36; 95% CI, −0.58 to −0.14; P = 0.002) 2. Body weight decreased by 1.6% with liraglutide versus an increase of 1.6% with placebo.

From a safety standpoint, 125 of 125 adolescents in the liraglutide arm reported at least one adverse event. That 100% rate sounds alarming in isolation, but 118 of 126 placebo-treated adolescents (93.7%) also reported adverse events. The difference was driven largely by gastrointestinal complaints. Serious adverse events occurred in 6 liraglutide-treated participants (4.8%) and 5 placebo-treated participants (4.0%), a gap the investigators described as not clinically meaningful 2.

Gastrointestinal Side Effects: The Most Frequent Concern

GI symptoms dominate the adverse-event profile. Nausea affected 42.4% of liraglutide-treated adolescents versus 14.3% on placebo. Vomiting occurred in 20.8% versus 8.7%, and diarrhea in 20.8% versus 11.9% 2.

These rates are higher than those reported in the adult SCALE Obesity and Diabetes trials. In the adult SCALE Obesity trial (N=3,731), nausea occurred in 40.2% of liraglutide-treated participants 3. The adolescent vomiting rate of 20.8% exceeded the adult rate of approximately 15%, which may reflect differences in reporting, body composition, or the faster relative dose escalation in smaller patients.

Most GI events were mild to moderate and peaked during the dose-titration phase (weeks 1 through 4). Slowing the titration schedule can reduce symptom severity. The FDA-approved titration starts at 0.6 mg daily for one week, increasing by 0.6 mg each subsequent week until reaching 3.0 mg. For adolescents with persistent nausea, some clinicians extend each titration step to two weeks, though this approach is off-label and requires clinical judgment 4.

Dehydration risk is real. Teenagers who are vomiting frequently may not self-hydrate as reliably as adults. Caregivers should be counseled to monitor fluid intake and watch for signs of dehydration, especially during summer sports or in warmer climates.

Thyroid C-Cell Tumor Warning

Liraglutide carries a boxed warning for thyroid C-cell tumors. In rodent studies, liraglutide at clinically relevant exposures caused dose-dependent thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). Whether GLP-1 receptor agonists cause thyroid C-cell tumors in humans remains unknown 5.

The drug is contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). No cases of MTC were reported in the SCALE Teens trial, and no cases attributable to GLP-1 agonists have been confirmed in post-marketing surveillance of pediatric patients. A 2022 population-based study using French and Swedish national health registries found no increased risk of thyroid cancer among adult GLP-1 receptor agonist users over a median follow-up of 3.9 years 6. Long-term adolescent data extending beyond the 82-week SCALE Teens observation window do not yet exist.

Routine calcitonin monitoring is not recommended by the Endocrine Society for patients on GLP-1 agonists 7. Baseline thyroid palpation and family history screening before prescribing remain standard practice.

Pancreatitis and Gallbladder Events

Acute pancreatitis is listed as a warning for all GLP-1 receptor agonists. In the SCALE Teens trial, no cases of pancreatitis were reported in either arm 2. Adult data from the LEADER cardiovascular outcomes trial (N=9,340) showed acute pancreatitis in 18 liraglutide-treated patients versus 23 placebo-treated patients over 3.8 years of median follow-up, a rate that was not statistically different between groups 8.

Gallbladder-related events deserve attention in adolescents. Rapid weight loss increases gallstone risk regardless of mechanism, and adolescents losing weight on liraglutide are not exempt. The adult SCALE Obesity trial reported cholelithiasis in 2.5% of liraglutide participants versus 1.0% on placebo 3. The SCALE Teens trial did not report gallbladder events as a separate category, but the sample size (N=251) was underpowered to detect a low-frequency event like cholelithiasis. Clinicians should have a low threshold for abdominal ultrasound in any adolescent presenting with right upper quadrant pain during treatment.

Growth Velocity and Pubertal Development

This is the concern with no parallel in adult prescribing. An adolescent who has not completed linear growth could theoretically be affected by appetite suppression, caloric restriction, or GI-mediated malabsorption during a period when growth hormone and sex steroids are driving skeletal elongation.

The SCALE Teens trial tracked height and Tanner staging. Over 56 weeks, mean height increased in both groups, and no statistically significant difference in linear growth velocity was observed between liraglutide and placebo arms 2. Tanner stage progression also did not differ. These are reassuring signals, but 56 weeks is short relative to the full pubertal growth window. A 12-year-old starting liraglutide may use it for years.

The AAP guideline recommends monitoring height velocity at every visit for adolescents on anti-obesity medications 1. If growth velocity falls below the 10th percentile for age and sex on two consecutive measurements, the prescribing team should reassess caloric intake, screen for nutritional deficiencies (iron, vitamin D, B12, zinc), and consider dose reduction or discontinuation.

Bone mineral density data in adolescents on liraglutide have not been published. Given the known association between caloric restriction and reduced bone accrual in teenagers, DXA monitoring may be warranted for patients on treatment longer than 12 months, particularly those with risk factors such as vitamin D deficiency or low calcium intake 9.

Mental Health Monitoring

The FDA label for Saxenda includes a warning about suicidal behavior and ideation. Early GLP-1 agonist trials in adults flagged a small number of psychiatric events, and the FDA extended this precaution to the adolescent population.

In the SCALE Teens trial, suicidal ideation was assessed using the Columbia Suicide Severity Rating Scale (C-SSRS). Suicidal ideation was reported in 4 liraglutide-treated participants and 1 placebo-treated participant. No suicide attempts occurred in either group 2. These numbers are too small for statistical inference, but they underscore the need for screening.

Adolescents with obesity already face elevated rates of depression and anxiety. A 2019 meta-analysis found that adolescents with obesity had 1.3 times the odds of depression compared with normal-weight peers 10. Disentangling drug effect from baseline risk is difficult. The practical recommendation: administer the Patient Health Questionnaire for Adolescents (PHQ-A) at baseline, at the end of dose titration (week 5), and every 3 months thereafter.

"We screen every adolescent starting a GLP-1 agonist with a validated instrument at baseline and at each titration step," noted guidance published by the Endocrine Society. "If new psychiatric symptoms emerge, the risk-benefit calculus of continuing the medication must be reassessed immediately" 7.

Rebound Weight Gain After Discontinuation

The SCALE Teens trial included a 26-week off-treatment follow-up period. During those 26 weeks, the liraglutide group regained a significant portion of their weight loss. BMI-SDS returned toward baseline levels, and by week 82 the between-group difference had narrowed substantially 2.

This rebound pattern mirrors adult data. The adult SCALE Maintenance trial showed that participants who discontinued liraglutide regained approximately 50% of their prior weight loss within 12 weeks 11. For adolescents and their families, this finding carries two implications. First, liraglutide is not a short-course treatment. If effective and tolerated, ongoing use should be expected. Second, if discontinuation is planned (for financial reasons, transition of care, or patient preference), a structured lifestyle intensification protocol and close follow-up should precede and accompany the taper.

Drug Interactions and Comorbidity Considerations

Liraglutide slows gastric emptying, which can affect the absorption of concomitant oral medications. For adolescents taking oral contraceptives, levothyroxine, or stimulant medications for ADHD, timing adjustments may be necessary. The FDA label recommends that patients using oral medications requiring threshold concentrations for efficacy should be monitored for changes in clinical response 5.

Adolescents with type 2 diabetes present a specific consideration. Liraglutide 1.8 mg (Victoza) is separately approved for glycemic control in patients aged 10 and older 12. The 3.0 mg obesity dose and the 1.8 mg diabetes dose should not be used simultaneously. If an adolescent has both obesity and type 2 diabetes, the prescriber must choose one indication and dose accordingly. The ELLIPSE trial (N=135) demonstrated that liraglutide 1.8 mg improved HbA1c by −0.64 percentage points versus placebo at 26 weeks in adolescents with type 2 diabetes 12.

Practical Monitoring Schedule for Prescribers

A structured monitoring protocol reduces risk and catches adverse events early. Based on the SCALE Teens data and AAP guidelines, the following schedule is appropriate for adolescents initiating liraglutide 3.0 mg:

Weeks 1 through 5 (titration): Weekly check-ins (telehealth acceptable) for GI tolerability, hydration status, and injection-site reactions. Administer C-SSRS or PHQ-A at week 1 and week 5.

Month 3: In-person visit. Measure height, weight, BMI-SDS. Assess GI symptoms. Repeat mental health screening. Basic metabolic panel and lipase if symptomatic.

Month 6: In-person visit. Repeat height velocity assessment. Fasting lipids, HbA1c (if diabetic), hepatic panel. Nutritional labs: 25-hydroxyvitamin D, ferritin, B12. Mental health screening.

Month 12 and annually: Full reassessment including height velocity trend, Tanner staging, nutritional labs, mental health screening, and explicit discussion of treatment continuation versus discontinuation 1. Consider DXA if risk factors for low bone density are present.

The 12-week efficacy checkpoint is a practical decision point. If an adolescent has not achieved at least a 1% reduction in BMI or 4% reduction in BMI-SDS by 12 weeks on the full 3.0 mg dose, the AAP guideline suggests reassessing adherence, diet, and activity before continuing 1.